When was hrt developed

References 1. Keep P. The ageing woman. In: Lauritzen C. Ageing and Estrogens. Volume 2. Karger; Basel, Switzerland: Kling J. Wilson R. In: In Feminine Forever. Evans M. Ziel H. Increased risk on endometrial carcinoma among users of conjugated estrogens. Smith D. Association of exogenous estrogen and endogenous carcinoma. Woodruff J. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens Premarin with medroxyprogesterone acetate or conjugated estrogens alone.

The Menopause Study Group. Lobo R. Hormone-replacement therapy: Current thinking. Grodstein F. Postmenopausal hormone therapy and mortality. Yaffe K. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. Stampfer M. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Grady D. Hormone therapy to prevent disease and prolong life in postmenopausal women.

Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. American Medical Association Guidelines for counseling postmenopausal women about preventive hormone therapy.

American College of Physicians. Too much of a good thing? Use of progestogens in the menopause: An international consensus statement. Hulley S. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Rossouw J. Anderson G. Hodis H. A window of opportunity: The reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res. Stuenkel C. Stevenson J. Coronary heart disease and menopause management: The swinging pendulum of HRT.

Manson J. Hsia J. Salpeter S. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. Mortality associated with hormone replacement therapy in younger and older women: A meta-analysis. Boardman H. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause.

Schierbeck L. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomized trial. Ravdin P. The decrease in breast-cancer incidence in in the United States. Buist D. Hormone therapy prescribing patterns in the United States. Guay M. Changes in pattern use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Drug Saf. Heitmann C. Clanget C. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women.

Menon U. Nelson H. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: Collaborative reanalyses of data from 51 epidemiological studies of 52, women with breast cancer and , women without breast cancer.

Chlebowski R. JAMA Oncol. Lancet Oncol. Santen R. The herbal medicine , black cohosh, may take the edge off hot flushes and sweats, but there is no data to support long-term use. There is also a rare liver condition that may be associated with the use of black cohosh. Commercially available vaginal moisturisers such as Replens may reduce vaginal dryness if used regularly. Consult your doctor about what will work best for you. This page has been produced in consultation with and approved by:.

Content on this website is provided for information purposes only. Information about a therapy, service, product or treatment does not in any way endorse or support such therapy, service, product or treatment and is not intended to replace advice from your doctor or other registered health professional. The information and materials contained on this website are not intended to constitute a comprehensive guide concerning all aspects of the therapy, product or treatment described on the website.

All users are urged to always seek advice from a registered health care professional for diagnosis and answers to their medical questions and to ascertain whether the particular therapy, service, product or treatment described on the website is suitable in their circumstances.

The State of Victoria and the Department of Health shall not bear any liability for reliance by any user on the materials contained on this website. Skip to main content. Hormonal system endocrine. Home Hormonal system endocrine. Hormone replacement therapy HRT and menopause. Actions for this page Listen Print. Summary Read the full fact sheet. On this page. These side effects will usually settle within the first few months of treatment and may include: breakthrough bleeding breast tenderness bloating nausea.

Breast cancer and HRT Women over 50 years of age who use combined oestrogen and progestogen progesterone replacement for less than five years have little or no increased risk of breast cancer. Cardiovascular disease and HRT Women over 60 have a small increased risk of developing heart disease or stroke on combined oral tablet HRT. Venous thrombosis and HRT Venous thromboses are blood clots that form inside veins. Endometrial cancer and HRT The endometrium is the lining of the uterus. Ovarian cancer and HRT The increased risk of ovarian cancer is very small and estimated to be one extra case per 10, HRT users per year.

Cholecystitis and HRT Cholecystitis is a disease in which gallstones in the gallbladder block ducts, causing infection and inflammation. HRT does not cause weight gain Weight gain at the menopause is related to age and lifestyle factors. Recent findings show that although not completely risk-free, HRT remains the most effective solution for helping with symptoms of menopause and is also effective for the prevention of osteoporosis.

It may also provide protection against heart disease. When deciding whether to have hormone replacement therapy HRT , it is also important to understand the risks.

You may have heard about a link between breast cancer and HRT. If you would like to start HRT, it is a good idea to have an initial discussion with your GP or practice nurse at your local primary care practice.

They can discuss the risks and benefits with you, so you can decide what is right for you. Every woman experiences the menopause differently, so there is no way of knowing how long symptoms will last and so how long HRT will need to be taken. Some women who have continued symptoms into the longer term, may need to keep taking HRT to help with symptoms and good quality of life. Further information about the benefits and risks of HRT.

Most women are able to stop taking HRT after their menopausal symptoms finish, which is usually two to five years after they start but in some cases this can be longer. Gradually decreasing your HRT dose is usually recommended, rather than stopping suddenly.

You may find that your menopausal symptoms come back after you stop HRT, but these should pass within a few months. Treatment may need to be restarted, usually at a lower dose. After you have stopped HRT, you may still need help to manage vaginal dryness and to prevent osteoporosis.

Read about the best ways to prevent osteoporosis. Such actions were, and continue to be, unduly influenced by a high level of media interest which has tended to attract some health scare headlines.

These new findings also show the additional benefits of HRT use for those initiating HRT in the age group, or for those less than 10 years past the menopause — trends to a lower risk from heart disease; a lower risk of death from any cause; no clear increased risk from stroke.

They also show a general increased risk for those starting HRT after the age of 60, which is later than normal UK clinical practice. It reported that women using estrogen only HRT had a reduced risk of breast cancer incidence and mortality but those on combined HRT had a slight increased risk of breast cancer incidence.

Importantly, this did not translate into an increased risk of mortality.